N@N

Antares Pharma Inc (AMEX:AIS), Up By 30.00% ($0.51) From $1.700 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bull

^{Published on 2011-12-28 13:40:22 - WOPRAI}
 

December 28, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, December 20th 2011 stating that Antares Pharma Inc (AMEX:AIS) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=ais&id=223957

At the time this story was written, Antares Pharma Inc (AMEX:AIS) is Up By $0.51 (30.00%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Antares Pharma Inc (AMEX:AIS) - Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. It offers injection devices, which include Medi-Jector Vision for insulin; Zomajet 2 Vision, Zomajet Vision X, Twin-Jector EZ II, and Tjet for human growth hormone; Vibex pressure assisted auto injector platform that enables a controlled pressure delivery of drugs into the body utilizing a spring power source; and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The company also develops/commercializes Anturol, an oxybutynin ATD (advanced transdermal delivery)gel, which is in Phase III clinical trials for the treatment of overactive bladder; Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; LibiGel, a transdermal testosterone gel that is in Phase III clinical studies for the treatment of female sexual dysfunction; Nestorone contraceptive formulation products, which has completed Phase II clinical trials; and Ropinerole to treat a central nervous system. Antares Pharma, Inc. markets its products to pharmaceutical companies primarily in the United States and Europe. It has collaborative arrangements and license agreements primarily with Teva Pharmaceutical Industries, Ltd.; BioSante Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Population Council, Ferring Pharmaceuticals BV; Eli Lilly and Company; JCR Pharmaceuticals Co., Ltd.; and Solvay Pharmaceuticals BV, as well as a strategic alliance with Uman Pharma. The company was formerly known as Medi-Ject Corporation and changed its name to Antares Pharma, Inc. in January 2001. Antares Pharma, Inc. was founded in 1979 and is based in Ewing, New Jersey.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net